Oral misoprostol versus mifepristone for cervical dilatation before vacuum aspiration in first trimester nulliparous pregnancy: a double blind prospective randomised study.
OBJECTIVE
To compare the effectiveness of oral misoprostol and mifepristone for cervical priming before first trimester termination of nulliparous pregnancy.


METHODS
Prospective double blind randomised study.


METHODS
Department of Obstetrics and Gynaecology, University of Hong Kong.


METHODS
One hundred nulliparous women undergoing termination of pregnancy between 8 and 12 weeks of gestation were recruited for this prospective randomised trial. The women were allocated to either the oral misoprostol or mifepristone group. Subjects in misoprostol group were given placebo and misoprostol 400 micrograms 36 h and 12 h respectively before vacuum aspiration. Subjects in mifepristone group were given 200 mg mifepristone and placebo 36 h and 12 h respectively prior to operation.


METHODS
Baseline pre-operative cervical dilatation, the incidence of side-effects, the amount of blood loss and duration of procedure.


RESULTS
There were no significant differences in the baseline cervical dilatation, incidence of side-effects, amount of blood loss and duration of procedure.


CONCLUSIONS
Misoprostol and mifepristone are of similar effectiveness for cervical priming prior to vacuum aspiration in nulliparous women. Misoprostol has additional advantages of being widely available and inexpensive.
Department of Obstetrics and Gynaecology, University of Hong Kong, Tsan Yuk Hospital, Hong Kong.
S W
SW
Ngai
K C
KC
Yeung
T
T
Lao
P C
PC
Ho
D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage* / Q000009:adverse effects; D000028:Abortion, Induced / Q000379:methods*; D000284:Administration, Oral; D000328:Adult; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D015735:Mifepristone / Q000008:administration & dosage* / Q000009:adverse effects; D016595:Misoprostol / Q000008:administration & dosage* / Q000009:adverse effects; D010298:Parity; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011446:Prospective Studies; D013607:Tablets; D014592:Uterine Hemorrhage / Q000139:chemically induced; D014620:Vacuum Extraction, Obstetrical
D000020:Abortifacient Agents, Nonsteroidal; D013607:Tablets; D016595:Misoprostol; D015735:Mifepristone